Breather Trainer Versus Pulmonary Rehabilitation on Cardiopulmonary Efficiency
COVID-19, COPD
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- SPO2 ≥ 93%
- Their age ranges from 30-40 years old.
- COPD patients GOLD1 (Mild FEV1≥80% predicted) and GOLD2 (Moderate 50% ≤FEV1<80%predicted) (Manian, 2019)
- patients diagnosed as post COVID-19 Pneumonia between 3 and 6 Months ago with CT scan and PCR testing.
- Their body mass index (BMI) ranged from 20 to 29.9kg/m2.
- Stable medical cases with dyspnea
Exclusion Criteria:
Patients who will meet one of the following criteria will be excluded from the study:
- patients with cardiac problems e.g. atrial fibrillation, left bundle-branch block, heart failure.
- Sever cases of COPD (FEV1/FVC< 50%)
- Mitral or aortic valvular disease, pericardial effusion.
- Recent myocardial infarction.
Sites / Locations
- Outpatient clinic, Faculty of Physical Therapy, Horus University, Egypt
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
The breather respiratory muscle trainer group
Diaphragmatic and localized breathing exercises group
40 patients (20 males and 20 females) will receive The breather respiratory muscle trainer for 30 minutes and mild interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks.
40 patients (20 males and 20 females) will receive diaphragmatic and localized breathing exercises ( especially Middle & Lower segments) and mild intensity interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks,